JP2021519296A - 治療用物質を標的送達するためのエキソソームの使用法 - Google Patents

治療用物質を標的送達するためのエキソソームの使用法 Download PDF

Info

Publication number
JP2021519296A
JP2021519296A JP2020551798A JP2020551798A JP2021519296A JP 2021519296 A JP2021519296 A JP 2021519296A JP 2020551798 A JP2020551798 A JP 2020551798A JP 2020551798 A JP2020551798 A JP 2020551798A JP 2021519296 A JP2021519296 A JP 2021519296A
Authority
JP
Japan
Prior art keywords
exosomes
cancer
protein
disorder
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551798A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019191444A5 (ko
Inventor
ラグー カルリ
ラグー カルリ
バレリー ルブルー
バレリー ルブルー
デ サンパイオ ペドロ コレア
デ サンパイオ ペドロ コレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2021519296A publication Critical patent/JP2021519296A/ja
Publication of JPWO2019191444A5 publication Critical patent/JPWO2019191444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020551798A 2018-03-28 2019-03-28 治療用物質を標的送達するためのエキソソームの使用法 Pending JP2021519296A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649057P 2018-03-28 2018-03-28
US62/649,057 2018-03-28
PCT/US2019/024603 WO2019191444A1 (en) 2018-03-28 2019-03-28 Use of exosomes for targeted delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
JP2021519296A true JP2021519296A (ja) 2021-08-10
JPWO2019191444A5 JPWO2019191444A5 (ko) 2022-04-04

Family

ID=68060505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551798A Pending JP2021519296A (ja) 2018-03-28 2019-03-28 治療用物質を標的送達するためのエキソソームの使用法

Country Status (7)

Country Link
EP (1) EP3773747A4 (ko)
JP (1) JP2021519296A (ko)
KR (1) KR20200136978A (ko)
CN (1) CN112533643A (ko)
AU (1) AU2019243179A1 (ko)
CA (1) CA3095136A1 (ko)
WO (1) WO2019191444A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900007785A1 (it) * 2019-05-31 2020-12-01 Univ Degli Studi Milano Vescicole extracellulari per veicolare farmaci terapeutici o diagnostici
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
WO2021119552A1 (en) * 2019-12-13 2021-06-17 Lawrence Livermore National Security, Llc Nanotube-vesicle compositions and uses thereof
CN114774471A (zh) * 2022-05-10 2022-07-22 厦门星际诺康细胞科技有限公司 一种呈现il27稳转细胞及其构建方法、呈现il27工程化外泌体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムdna、rnaおよびタンパク質の分析

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
WO2014076137A1 (en) * 2012-11-13 2014-05-22 Lötvall Jan Delivery of therapeutic agent
BR112015002626A2 (pt) * 2012-11-29 2017-09-26 Yeda Res & Dev métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
JP2019501179A (ja) * 2015-12-30 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞由来ベシクルの向上された生成および単離のための方法
TWI601741B (zh) * 2016-07-11 2017-10-11 財團法人國家衛生研究院 利用前列腺素受體ep4-拮抗劑誘導幹細胞製造含有高囊泡含物之外泌體囊泡的方法及其應用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムdna、rnaおよびタンパク質の分析
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, vol. 21, no. 1, JPN6023010226, 2013, pages 185 - 191, ISSN: 0005010738 *

Also Published As

Publication number Publication date
CA3095136A1 (en) 2019-10-03
EP3773747A4 (en) 2022-02-23
EP3773747A1 (en) 2021-02-17
KR20200136978A (ko) 2020-12-08
WO2019191444A1 (en) 2019-10-03
CN112533643A (zh) 2021-03-19
AU2019243179A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
US10959952B2 (en) Use of exosomes for the treatment of disease
JP2021519296A (ja) 治療用物質を標的送達するためのエキソソームの使用法
JP2020537545A (ja) mRNAの細胞内送達のためのペプチドおよびナノ粒子
JP2024059816A (ja) エキソソーム関連遺伝子編集を用いてがんを処置するための方法および組成物
JP2021020952A (ja) Tp53のヘミ接合性喪失を保有するがんを処置する方法
US20210369858A1 (en) Use of exosomes for targeted delivery of therapeutic agents
Allemailem et al. Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management
Dong et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer
Ogunnaike et al. Bovine mammary alveolar MAC-T cells afford a tool for studies of bovine milk exosomes in drug delivery
JP2021521126A (ja) エキソソームを用いたがん遺伝子に対する治療的な標的指向化の方法
JP2021522164A (ja) エキソソームを用いる腫瘍抑制因子の治療的調整法
CN117159495A (zh) 脂质纳米颗粒及其应用
CN118308350A (en) CGAS-STING pathway agonists and uses thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230608

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513